Please login to the form below

Not currently logged in
Email:
Password:

Akynzeo

This page shows the latest Akynzeo news and features for those working in and with pharma, biotech and healthcare.

Merck plans expanded filing for Emend this year

Merck plans expanded filing for Emend this year

Generics aside, competition is building in the CINV sector. Last October the FDA approved Eisai's combination Akynzeo (netupitant and palonosterol), while Tesaro's oral and injectable NK1 antagonist rolapitant was

Latest news

  • Eisai wins US approval for chemotherapy side effects drug Eisai wins US approval for chemotherapy side effects drug

    Combined, these studies involved 1, 720 people receiving chemotherapy, with groups split between those taking Akynzeo and those on Aloxi. ... For Akynzeo the figures were 90.4% and 80.6% respectively, while for the Aloxi arm the figures were 80.1% and

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics